

Multijurisdictional Contractor Advisory Committee (CAC) June 26, 2019, Regarding Pharmacogenomics

The purpose of this meeting is to discuss the role of pharmacogenomic testing as it relates to the selection of individualized pharmaceuticals in the care of the Medicare beneficiary. While CAC panels do not make coverage determinations, the MACs significantly benefit from their advice and guidance.

Agenda

- 1:00 – 1:10 Introductory comments by Earl Berman
- 1:10 – 1:15 Introduction of panel members and explanation of the how the panel will function by Paul Gerrard
- 1:15 – 2:30 Panelists answer questions spending roughly 15 minutes each. Other than Paul Gerrard speaking to move the session along, panelists only will speak at this time, and only the panelist who has the floor.
- 2:30 – 3:00 Follow-up questions asked by Paul Gerrard and/or other CMDs
- 3:00 – 4:00 CAC Members who wish to speak will be able to speak either giving their own thoughts or asking additional questions of the panelists.